N2Tech Recruits Moderna Co-Founder in the US... "Entering Vaccine and Therapeutics Import Business"

[Asia Economy Reporter Yoo Hyun-seok] N2Tech announced on the 23rd that it will recruit founding members of Moderna, a pharmaceutical company developing a novel coronavirus (COVID-19) vaccine, as inside directors. It also plans to add medical vaccine and therapeutic businesses, as well as vaccine import and supply businesses, to its business objectives to actively promote pharmaceutical distribution business.

N2Tech plans to appoint Dr. Robert Langer and Mr. Ian Chen, founding members of Moderna who are major shareholders and board members, as inside directors at the extraordinary general meeting on the 6th of next month. Dr. Robert Langer, a professor at the Massachusetts Institute of Technology (MIT), holds a bachelor's degree in Chemical Engineering from Cornell University and a Ph.D. in Chemical Engineering from MIT. He is regarded as the "God of Startups" in Boston, the world's largest bio-cluster.

He has filed over 1,350 patents and authored more than 1,400 scientific papers. He received the "Queen Elizabeth Prize for Engineering," known as the "Nobel Prize of Engineering," and was selected as the "most cited engineer in history" by Google Scholar, among other honors.

Additionally, the planned appointee Ian Chen holds a bachelor's degree in Biology from Brown University and an MBA from Harvard Business School. He has worked as an executive at global companies such as Morgan Stanley.

N2Tech plans to leverage Professor Robert Langer's network to promote medical vaccine and therapeutic businesses. In the context of the COVID-19 pandemic, the company aims to import vaccines and therapeutics from the United States to contribute to securing the government's goal of "health sovereignty."

An N2Tech official stated, "We have entered the bio business by recruiting Professor Langer, a board member of Moderna, one of the leading companies in COVID-19 vaccine development, as an inside director. We plan to import vaccines and therapeutics that can show results within this year by utilizing Professor Langer's infrastructure." He added, "Through the production of nano masks launched this year, we will promote K-quarantine to the global market and leap forward as a bio company actively responding to emerging infectious diseases through vaccine and therapeutic distribution."

Along with this, N2Tech plans to add medical vaccine and therapeutic businesses, vaccine import and supply businesses, and the manufacturing, sales, and import/export of pharmaceuticals, quasi-drugs, cosmetics, and health functional food materials and finished products to its new business objectives.